The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Mucosal Melanoma Clinical Trial

Official title:

A Phase II Randomized, Control, Multi-center Study of Recombinant Humanized Anti-PD-1 mAb for Injection Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03178123
• Other study ID #: Junshi-JS001-010
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 31, 2017
• Est. completion date: April 30, 2025

Study information

• Verified date: September 2020
• Source: Shanghai Junshi Bioscience Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II randomized, control, multi-center study of recombinant humanized anti-PD-1 mAb for injection compared to high-Dose interferon in patients with mucosal melanoma that has been removed by surgery.

Description:

This is a multi-centre，open, randomized, parallel-group study of mucosal melanoma adjuvant therapy to evaluate the efficacy of recombinant humanized anti-PD-1 mAb for injection compared to high-Dose interferon in patients with mucosal melanoma that has been removed by surgery.There will be 220 subjects enrolling the study, and randomized 1:1 grouped into recombinant humanized anti-PD-1 mAb for injection group (experimental group) or interferon group (control group).Each group will have 110 subjects.Random stratification factor is the disease stage (I vs II vs III).The whole research lasts about 60 months.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 220
• Est. completion date: April 30, 2025
• Est. primary completion date: April 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male and Female aged between 18 and 75 years are eligible;

• It was confirmed by histopathology that it was a mucosal melanoma;

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;

• Complete excision of primary focal area, surgical incision; All patients must have disease-free status documented by a complete physical examination and imaging studies prior to registration;

• No adjuvant therapy was received;

• No treatment contraindication, peripheral blood, normal liver, kidney function and electrocardiogram are normal; WBC=4.0×10^9/L,PLT=100×10^9/L,Hgb=90g/L; serum urea nitrogen, cr=ULN; ALT,AST,TBI=1.5*ULN,

• Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 12 months after the last dose of study drug;

• FT3,FT4 and TSH is normal;

• Must have read, understood, and provided written informed consent voluntarily. Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.

Exclusion Criteria:

• Prior treatment with anti-PD-1/PD-L1/PD-L2 antibody;

• Hypersensitivity to recombinant humanized anti-PD-1 monoclonal mAb or its components;

• Skin melanoma, ocular melanoma, original unknown melanoma;

• The primary lesion was incomplete;

• The examination suggests that the tumor remains or metastases;

• Pregnant or nursing;Women with fertility but not contraception;

• There are severe acute infections that are not controlled;There is a suppurative and chronic infection, and the wound is deferrable;

• Those who had serious heart disease;

• Psychiatric medicines abuse without withdrawal, or history of psychiatric illness.

• Patients with other tumor;

• Participate in other clinical studies at the same time;

• Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA (>500IU/ml);

• Patients with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism or hypothyroidism;

• Prior live vaccine therapy within past 4 weeks;

• Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events

Related Conditions & MeSH terms

• Melanoma
• Mucosal Melanoma

Intervention

Biological:
• humanized anti-PD-1 monoclonal antibody Toripalimab
humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
• high-dose recombinant interferon a-2B
15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Junshi Bioscience Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence-free survival rate	to evaluate the Recurrence free survival (RFS) of the patients with mucosal melanoma treated by JS001 and high-Dose interferon	5 years
Secondary	Distant metastases-free survival	to evaluate the distant metastases-free survival of the patients with mucosal melanoma treated by JS001 and high-Dose interferon	5 years
Secondary	recurrence - free survival rate at 3 years	to evaluate the recurrence - free survival rate at 3 years of the patients with mucosal melanoma treated by JS001 and high-Dose interferon	3 years
Secondary	Overall survival (OS)	to evaluate the Overall survival (OS) of the patients with mucosal melanoma treated by JS001 and high-Dose interferon	5 years
Secondary	Number of participants with treatment-related adverse events	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	5 years